CPT-6281 / Captor Therap - LARVOL DELTA

A phase 1 study of CT-01, a dual molecular glue degrader of GSPT1 and NEK7, as monotherapy and in combination with everolimus in patients with hepatocellular carcinoma. (ASCO 2026) - "Targeted degradation of GSPT1 and NEK7 represents a promising new therapeutic strategy for cancer treatment. CT-01, a molecular glue, has successfully completed preclinical development. Its safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy is being evaluated in a Phase 1 clinical trial."

Clinical • Combination therapy • Monotherapy • P1 data • Hepatocellular Cancer • Oncology • Solid Tumor • Targeted Protein Degradation • GSPT1 • IL1B

A phase 1 clinical trial of CT-01, a dual degrader of GSPT1 and NEK7, alone or in combination with everolimus for the treatment of hepatocellular carcinoma (AACR 2026) - "CT-01, a molecular glue has just completed preclinical development, and its safety, pharmacokinetics, pharmacodynamics and preliminary efficacy will be evaluated in a phase 1 study commencing in 2025 - an open-labeled, dose escalation and dose expansion study of CT-01 as monotherapy and combination with everolimus in subjects with intermediate or advanced hepatocellular carcinoma. Interim clinical data from this study will be available at the time of presentation"

Clinical • Combination therapy • First-in-human • P1 data • Hepatocellular Cancer • Oncology • Solid Tumor • GSPT1 • IL1B

Study of CT-01 as Monotherapy and Combination Therapy in Subjects With Intermediate or Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - P1 | N=141 | Not yet recruiting | Sponsor: Captor Therapeutics S.A.

Monotherapy • New P1 trial • Hepatocellular Cancer • Oncology • Solid Tumor

Development of small molecule degrader of G1 to S phase Transition 1 (GSPT-1) for the hepatocellular carcinoma treatment (LCS 2025) - "Presented results indicate that targeting GSPT-1 protein by induction of its degradation could represent a new and effective strategy for cancer treatment. CT-01, a molecular glue has just completed preclinical development, and its safety, pharmacokinetics and pharmacodynamics will be evaluated in a phase 1 study commencing in 2025 – an open-labeled, dose escalation and dose expansion study of CT-01 as monotherapy and combination therapy in subjects with intermediate or advanced hepatocellular carcinoma."

Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor • GSPT1

Captor Therapeutics Publishes Q1 2023 Financial Results (GlobeNewswire) - "Lead asset CT-01 on track for clinical trial application authorization in Q3 2023."

New trial • Oncology

Captor Therapeutics Announces Three-Year Strategic Objectives (GlobeNewswire) - "Initiate the clinical development by Captor of its advanced projects CT-01 (Hepatocellular carcinoma) and CT-03 (haematological malignancies) in 2023 and 2024 respectively, with clinical data readouts in 2024 and 2025. Advance Captor's early pipeline assets in inflammation (CT-02, CT-05) to in-vivo proof of efficacy in 2023 as a prelude to collaborative development."

Clinical data • New trial • Preclinical • Gastrointestinal Cancer • Hematological Malignancies • Hepatocellular Cancer • Immunology • Leukemia • Liver Cancer • Oncology • Solid Tumor

Captor Therapeutics Reports Q3 2022 Results and Provides Business Update (GlobeNewswire) - "Captor Therapeutics...reports its financial results for the third quarter of 2022 and provides a business update. The Company has made further substantial progress in the development of its lead programs throughout the period, most notably CT-01, with the selection of a drug candidate and the initiation of the necessary steps to generate the data required to commence clinical trials in patients...CT-01 is Captor’s lead asset and is being developed as a treatment for hepatocellular carcinoma (a form of liver cancer)...Captor remains on track to initiate a clinical trial in 2023."

New trial • Gastrointestinal Cancer • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor

Captor Therapeutics Nominates the Molecular Glue CPT-6281 as Drug Candidate to Enter CTA/IND-Enabling Studies for the Treatment of Hepatocellular Carcinoma (GlobeNewswire) - "Captor Therapeutics S.A....announces that it has selected CPT-6281 as drug candidate for the CT-01 project, which will initially focus on the clinical development of the asset as a TPD treatment against hepatocellular carcinoma (HCC). The announcement of the drug candidate confirms that CPT-6281 is on track to enter the clinical phase in 2023....The CDMO will produce sufficient amounts of drug candidate to complete the preclinical studies required to support a clinical trial application filing with the regulators next year."

IND • New trial • Gastrointestinal Cancer • Hepatocellular Cancer • Liver Cancer • Oncology

Captor Therapeutics announces molecular targets of CT-01 program developing TPD therapy for hepatocellular carcinoma (GlobeNewswire) - "Compelling in-vitro and in-vivo preclinical data demonstrate that CT-01 candidate compounds induce degradation of Eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1), Sal-like protein 4 (SALL4) and another undisclosed neo-substrate with essential function in tumorigenesis. GSPT1 is a protein involved in the termination of translation, a process in which ribosomes synthesize proteins after the transcription of DNA to RNA. There is a demonstrated link between GSPT1 degradation and antitumor activity. SALL4 is a transcription factor expressed in the human fetal liver and silenced in adults but often re-expressed in HCC patients, which correlates with poor prognosis....Captor Therapeutics plans to advance CT-01 towards Investigational New Drug Application (IND)-enabling studies and to initiate clinical trials in 2023."

New trial • Preclinical • Gastrointestinal Cancer • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor

Captor Therapeutics Presents Compelling In Vivo Proof-of-Concept Data from CT-01 Program in Hepatocellular Carcinoma (GlobeNewswire) - "Captor Therapeutics...announces preclinical proof-of-concept data from one of its core pipeline projects designated CT-01, which is focused on the development of TPD therapy for hepatocellular carcinoma (HCC). The in vivo proof-of-concept data confirm the potent antitumor activity of two CT-01 lead compounds in a liver cancer mouse xenograft model and demonstrate that oral administration of these two CT-01 candidates results in complete tumor regression in a Hep 3B2.1-7 mouse model of HCC."

Preclinical • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor